Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxetumomab Pasudotox-tdfk and Rituximab/Ruxience for Relapsed Hairy Cell Leukemia
NCT03805932Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Antibody Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of moxetumomab pasudotox in hairy cell leukemia (HCL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Safe Dose of Moxetumomab Pasudotox-tdfk at 4 weeks and Recommended Safe Dose of Rituximab/Ruxience at 4 weeks. Started Oct 2019; status: active, not recruiting.
02
Drugs
moxetumomab pasudotox
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT03805932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805932.